CEMM FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2013. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Singapore. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are SEC DEP FOR ENVIRONMENT FOOD &, CEMM FORSCHUNGSZENTRUM FUR MOLEKULARE MEDIZIN GMBH and CHU SAINTE JUSTINE.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 8 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Singapore | 2 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Kralovics Robert | 5 |
#2 | Gisslinger Heinz | 4 |
#3 | Klampfl Thorsten | 4 |
#4 | Superti-Furga Giulio | 4 |
#5 | Snijder Berend | 3 |
#6 | Kubicek Stefan | 2 |
#7 | Vladimer Gregory Ian | 2 |
#8 | Li Jin | 2 |
#9 | Schliehe Christopher | 1 |
#10 | Rebsamen Manuele | 1 |
Publication | Filing date | Title |
---|---|---|
WO2017191203A1 | Multiwell imaging plate and method for incubating non-adherent cells | |
WO2016079321A1 | Antagonists of setdb2 for use in the therapy of infectious diseases | |
WO2015036599A1 | Mutant calreticulin for the diagnosis of myeloid malignancies | |
EP2929881A1 | Medical use of artemisinin compounds and gephyrin agonists |